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In this presentation, we will discuss recent biocompatibility data obtained using our gamma stable fluoropolymer
platform and its advantage in a modern manufacturing environment for the handling of almost any biological
fluids.
Single-use, disposable solutions are now widely accepted as
gold standard in the biopharmaceutical industry covering every
single steps of the drug manufacture process. From earlystage small scale R&D project, upstream production with
several thousand-liters bioreactors, downstream process, API
formulation up to critical fill & finish and transport applications,
the industry is taking a shift with a significant breakthrough
reported in 2021: the largest GMP facility in the world using
single-use (from 200L to 4,000 L) bioreactors has been publicly
announced this year with a global single-use bioreactor
workforce of over 150,000 L (with extension plans for 2024 to
expand its use of disposable bioreactors to over 430,000 L).
The presentation will be focusing with recent case studies and
analytical technology data obtained in the lab on carefully
selected molecular entities / submicron particles in order to
support various applications such as large-scale
bioprocessing/banking of mammalian cells, cell & gene therapy
(adenovirus), critical vaccinology program (mRNALNP/liposomes) as well as purified proteins.
Recent trends and challenges in (disposable) materials and technologies used in the decentralized
biopharmaceutical industry will be also discussed.
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